RxDoctor Payments Data

Dennis Hanney, DO

Cardiovascular Disease · Jupiter, FLNPI 1669411484

Payments from drug & device makers

$1,083in general payments, 2019–2025

Across 33 payments — averaging $32.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$239
  • Novo Nordisk$212
  • Medtronic$137
  • Impulse Dynamics (USA) Inc.$132
  • Dynasplint Systems Inc.$94
  • GSK$71
  • plus $198 from 10 others

What the payments were for

  • Food & beverage$1,083100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,083 in reported general payments places this provider in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$60,580
Medicare patients
206
Services billed
571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$74,581
XareltoRivaroxaban22$20,847
Metoprolol Succinate239$2,786
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide67$755
Rosuvastatin Calcium57$657
Ezetimibe21$624
Nifedipine ErNifedipine18$554
Atorvastatin Calcium43$526
Amlodipine Besylate70$454
Losartan Potassium49$348
Lisinopril19$230
Amiodarone Hcl12$185
ClopidogrelClopidogrel Bisulfate18$178
Furosemide36$149
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide25$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$74,58170 claims
Johnson & JohnsonXarelto$17$20,84722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →